Search Results - V. Pechtner

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?

    Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same? by R. Gentilella, V. Pechtner, Antonella Corcos, Agostino Consoli

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus

    Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus by G. Reach, V. Pechtner, R. Gentilella, Antonella Corcos, Antonio Ceriello

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement

    Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement by Francesco Giorgino, A. Penfornis, V. Pechtner, R. Gentilella, Antonella Corcos

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

    Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) by Francesco Giorgino, Marian Benroubi, Jui‐Hung Sun, Alan G. Zimmermann, V. Pechtner

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Treatment for 2 mo with n−3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study

    Treatment for 2 mo with n−3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a ran... by Morvarid Kabir, Geraldine Skurnik, Nadia Naour, V. Pechtner, Emmanuelle Meugnier, Sophie Rome, Annie Quignard‐Boulangé, Hubert Vidal, Gérard Slama, Karine Clément, Michèle Guerre-Millo, Salwa W. Rizkalla

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Treatment for 2 mo with n−3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study

    Treatment for 2 mo with n−3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a ran... by Morvarid Kabir, Geraldine Skurnik, Nadia Naour, V. Pechtner, Emmanuelle Meugnier, Sophie Rome, Annie Quignard‐Boulangé, Hubert Vidal, Gérard Slama, Karine Clément, Michèle Guerre-Millo, Salwa W. Rizkalla

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: